Compositions and methods for treating neurodegenerative disorders

5-benzylaminosalicylic acid compounds effectively treat cognitive dysfunction syndrome in companion animals by inhibiting oxidative stress and inflammation, providing long-lasting improvements in cognitive function and behavioral symptoms.

JP7578989B2Active Publication Date: 2024-11-07GNT PHARMA CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2021538053
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-12-28
Filing Date
2019-12-26
Publication Date
2024-11-07
Estimated Expiration
2039-12-26

AI Technical Summary

Technical Problem

There is an unmet medical need for disease-modifying compounds to treat cognitive dysfunction syndrome (CDS) in companion animals, as existing treatments like selegiline provide only short-term symptomatic relief and there are no effective long-term solutions for neurological disorders such as CDS, dysthymia, and confusion syndromes in dogs and cats.

Method used

The use of 5-benzylaminosalicylic acid compounds or their pharmaceutically acceptable salts, particularly 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid, for oral administration to inhibit oxidative stress and inflammation, thereby treating cognitive and neurobehavioral disorders by simultaneously targeting microsomal prostaglandin E synthase 1 (mPGES-1).

Benefits of technology

The compounds significantly improve cognitive and neurobehavioral functions in companion animals, with effects lasting at least four weeks after the last dose, reducing symptoms like disorientation, memory loss, and behavioral changes associated with CDS, and potentially halting disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578989000001
    Figure 0007578989000001
  • Figure 0007578989000002
    Figure 0007578989000002
  • Figure 0007578989000003
    Figure 0007578989000003
Patent Text Reader

Abstract

The present disclosure relates to a pharmaceutical composition for treating cognitive decline in companion animals, the pharmaceutical composition comprising a 5-benzylaminosalicylic acid compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient suitable for, for example, oral administration. Compositions comprising a 5-benzylaminosalicylic acid compound of formula (I) or a pharmaceutically acceptable salt thereof can be used to treat progressive cognitive impairment in neurological disorders, including cognitive dysfunction syndrome (CDS), dysthymia, regressive depression, and confusion syndrome, in elderly companion animals.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 785,903, filed December 28, 2018, which is incorporated by reference in its entirety.

[0002] Technical Field The present disclosure relates to a pharmaceutical composition for treating cognitive impairment in elderly companion animals, comprising a 5-benzylaminosalicylic acid compound of formula (I) or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient suitable for oral administration.The present disclosure relates to a method for treating cognitive decline, including canine CDS, dysthymia, involutive depression, and confusional syndrome. [Background technology]

[0003] The number of companion animals is gradually increasing around the world. The number of pet dogs and pet cats in the top 20 countries is estimated at approximately 256 million and 236 million, respectively. Pet dogs and cats are living much longer these days due to improved nutrition, disease treatment, and good veterinary and owner care. Thus, there is an increasing interest in treating age-related diseases in companion animals.

[0004] Many old or geriatric dogs and cats suffer from cognitive impairment due to nervous system disorders, including CDS, dysthymia, degenerative depression, and confusion syndrome. Cognitive impairment is defined as problems remembering, learning new things, concentrating, or making decisions that may affect daily life. CDS is an age-related degenerative brain disease in dogs and cats. The prevalence of CDS has been reported to range from 14% to 60% in dogs over 8 years of age [1-4]. Other reports have shown that 62% of companion dogs aged 11-16 years suffer from CDS, with the prevalence increasing significantly with age [5]. Thus, a large number of dogs suffer from CDS, which can worsen the human-animal bond and reduce the animal's quality of life, resulting in a shorter survival time for the animal [6-8].

[0005] The pathophysiological changes seen in canine CDS include cerebral cortical and basal ganglia atrophy, increased ventricular size, demyelination, increased size and number of glial cells, neuronal loss, axonal degeneration, and accumulation of beta-amyloid plaques in cortical regions, especially the hippocampus [6, 9, 10]. Cats with CDS also have a decreased number of neurons, beta-amyloid deposits, and increased glial cells, similar to canine CDS. In contrast to human Alzheimer's disease (AD), the neurofibrillary tangles commonly seen in AD have not been identified in the brains of dogs and cats with CDS, suggesting that canine and feline CDS can be distinguished from AD

[11] .

[0006] Dogs and cats diagnosed with CDS show progressive impairment in cognitive and neurological function and exhibit a variety of behavioral problems, including getting lost in the home, becoming less active during the day, not responding to family members or other familiar animals, not responding when called by name, walking in circles, or urinating in unusual places [10, 12-15].

[0007] Although a rapid increase in the number of dogs and cats affected by CDS has been observed in recent years, CDS remains an unmet medical need. Selegiline, a selective irreversible inhibitor of monoamine oxidase B (MAO-B), is the only medication approved by the FDA for the treatment of CDS

[16] . Previous reports have shown that selegiline enhances cognitive function and improves behavioral function. However, recent data have shown that its beneficial effects do not persist for a long time, indicating that selegiline therapy is only a symptomatic treatment. For example, cognitive function in dogs with CDS improved within the first 2 weeks after selegiline treatment, but the beneficial effects in most of the dogs disappeared 8 weeks after treatment [17-19]. Furthermore, a large-scale clinical trial involving 474 dogs over 8 years of age affected by CDS concluded that selegiline treatment should be administered at the early onset of clinical signs

[19] .

[0008] Many non-pharmacological therapies are commercially available, including dietary supplements with antioxidants, L-carnitine and omega-3 fatty acids, aimed simply at improving the well-being of dogs by relieving anxiety and aiding cognitive function. For optimal results, such dietary supplements should be initiated at an early stage of canine CDS. As there is no cure for canine and feline CDS, there is a need to develop disease-modifying compounds and methods that can halt or slow the progression of CDS.

[0009] Between 2002 and 2012, over 400 clinical trials were conducted to treat AD, but memantine, a low- to medium-affinity N-methyl-D-aspartate receptor antagonist, was the only drug approved for symptomatic treatment of AD based on the finding that it showed modest improvements in mental function and ability to perform daytime activities in moderate to severe AD. Since then, large-scale Phase III clinical trials of drugs targeting beta-amyloid, inflammation, or oxidative stress have been conducted for AD, but all have not shown beneficial effects, worsening the situation. However, nearly all failed drugs reduced amyloid plaque burden and improved cognitive function in two standard mouse models of AD, Tg2576 and APP / PS1, which carry familial AD mutations in genes, mutant amyloid precursor protein (APP), or overexpress APP and presenilin, respectively. Thus, the pharmacological efficacy of drug candidates proven in preclinical animal models of AD has not translated into efficacy in treating AD in humans.

[0010] Detailed Description 5-Benzylaminosalicylic acid compounds, or their pharma- ceutical acceptable salts, have been used to treat AD and neurodegenerative diseases (U.S. Patent No. 6,964,982). Previous studies have validated 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid as a potent spin trap and microsomal prostaglandin E(2) synthase 1 (mPGES-1) inhibitor effective at nanomolar concentrations, which not only blocked neuronal cell death, axonal degeneration, and autophagosome formation, but also increased motor function activity and survival in a mouse model of amyotrophic lateral sclerosis

[20] .

[0011] 5-benzylaminosalicylic acid compounds or their pharma- ceutical acceptable salts were explored for the treatment of CDS in companion animals. Surprisingly, oral administration of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid for more than 4 weeks significantly improved cognitive and neurobehavioral function in aged companion dogs suffering from severe CDS. Furthermore, the beneficial effects of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid were maintained for at least 4 weeks after the last administration. Thus, it was suggested that 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid could be a potential therapeutic option for treating CDS by inhibiting both oxidative stress and inflammation. In some embodiments, the present disclosure relates to compositions and methods comprising 5-benzylaminosalicylate compounds of formula (I) or pharma- ceutically acceptable salts thereof for treating cognitive and / or neurobehavioral deficits in companion animals, e.g., in neurological diseases. Summary of the Invention [Problem to be solved by the invention]

[0012] Thus, the present disclosure provides pharmaceutical compositions and methods useful for treating cognitive and / or neurobehavioral disorders in neurological disorders such as CDS, dysthymia, regressive depression and confusion syndrome in companion animals. [Means for solving the problem]

[0013] The present disclosure provides a compound of formula (I):

[0014] [ka] (In the formula, X is CO, SO2 and (CH2) n is selected from R1 is selected from hydrogen, C1-C6 alkyl and C1-C6 alkanoyl; R2 is selected from hydrogen and C1-C6 alkyl; R3 is selected from hydrogen and a C1-C5 acetyl group; R4 is selected from a phenyl group, a phenoxy group, and a 5-10 membered aryl group unsubstituted or substituted with one or more substituents each independently selected from nitro, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C5 alkoxy, and C1-C5 haloalkoxy; n is an integer from 1 to 5, inclusive; or a pharma- ceutically acceptable salt thereof.

[0015] The present disclosure provides a method of treating cognitive and / or neurobehavioral disorders, for example in neurological diseases, by administering to a companion animal in need thereof a compound of formula (I):

[0016] [ka] (In the formula, X is CO, SO2 and (CH2) n is selected from R1 is selected from hydrogen, C1-C6 alkyl and C1-C6 alkanoyl; R2 is selected from hydrogen and C1-C6 alkyl; R3 is selected from hydrogen and a C1-C5 acetyl group; R4 is selected from a phenyl group, a phenoxy group, and a 5-10 membered aryl group unsubstituted or substituted with one or more substituents each independently selected from nitro, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C5 alkoxy, and C1-C5 haloalkoxy; n is an integer from 1 to 5, inclusive; or a pharma- ceutically acceptable salt thereof.

[0017] In some embodiments, several compounds of formula (I) have been prepared and evaluated. In some embodiments, the compositions and methods include a 5-benzylaminosalicylic acid compound of formula (I) or a pharma- ceutically acceptable salt thereof.

[0018] In some embodiments, the 5-benzylaminosalicylic acid compound is 5-benzylaminosalicylic acid itself.

[0019] Preferred examples of 5-benzylaminosalicylic acid compounds include, but are not limited to, 2-hydroxy-5-phenethylamino-benzoic acid (compound 1), 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid (compound 2), 2-hydroxy-5-[2-(3-trifluoromethyl-phenyl)-ethylamino]-benzoic acid (compound 3), 5-[2-(3,5-bis-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 4), 2-hydroxy-5-[2-(2-nitro-phenyl)-ethylamino]-benzoic acid (compound 5), 5-[2-(4-chloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 6), 5-[2-(3,4-difluoro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 7), 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 8), 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 9), 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 10), 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 11), 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 12), 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 13), 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 14), 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy- 5-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 8), 5-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 9), 5-[2-(2-fluoro-4-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 10), 2-hydroxy-5-[2-(4-methoxy-phenyl)-ethylamino]-benzoic acid (compound 11), 2-hydroxy-5-(2-o-tolyl-ethylamino)-benzoic acid (compound 12), 2-hydroxy-5-(3-phenyl-propylamino)-benzoic acid (compound 13), 2-hydroxy-5-[3-(4-trifluoromethyl-phenyl)-propylamino]-benzoic acid (compound 14), 5-[3-(4-fluoro-phenyl)-propylamino]-2-hydroxy-benzoic acid (compound 15), 5-[3-(3,4-Dichloro-phenyl)-propylamino]-2-hydroxy-benzoic acid (compound 16), 2-hydroxy-5-(3-p-tolyl-propylamino)-benzoic acid (compound 17), 2-acetoxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid (compound 18), 5-[2-(2-chloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid (compound 19), 5-benzylaminosalicylic acid (compound 20), 5-(4-nitrobenzyl)aminosalicylic acid (compound 21), 5-(4-chlorobenzyl)aminosalicylic acid (compound 22), 5-(4-trifluoromethylbenzyl)aminosalicylic acid (compound 23), 5-(4-fluorobenzyl)aminosalicylic acid (compound 24), 5-(4-methoxybenzyl) These include aminosalicylic acid (Compound 25), 5-(2,3,4,5,6-pentafluorobenzyl)aminosalicylic acid (Compound 26), 5-(4-nitrobenzyl)amino-2-hydroxyethyl benzoate (Compound 27), 5-(4-nitrobenzyl)-N-acetylamino-2-hydroxyethyl benzoate (Compound 28), 5-(4-nitrobenzyl)-N-acetylamino-2-acetoxyethyl benzoate (Compound 29), 5-(4-nitrobenzoyl)aminosalicylic acid (Compound 30), 5-(4-nitrobenzenesulfonyl)aminosalicylic acid (Compound 31), 5-[2-(4-nitrophenyl)-ethyl]aminosalicylic acid (Compound 32) and 5-[3-(4-nitro-phenyl)-n-propyl]aminosalicylic acid (Compound 33). In certain preferred embodiments, the compound of formula (I) is compound 2, 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid, or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula (I) has the following structure:

[0020] [ka]

[0021] The 5-benzylaminosalicylic acid compounds or pharma- ceutically acceptable salts thereof of the present disclosure may be prepared by, but is not limited to, the reaction schemes shown in US Pat. No. 6,573,402.

[0022] In some embodiments, the cognitive and / or neurobehavioral disorder is CDS, dysthymia, retrograde depression or confusion syndrome.In some embodiments, the compound of formula (I) treats the cognitive and / or neurobehavioral disorder of companion animals.In some embodiments, the cognitive and / or neurobehavioral disorder is CDS.

[0023] In some embodiments, the treatment of cognitive and / or neurobehavioral disorders is by simultaneous pharmacological inhibition of oxidative stress and inflammation. In some embodiments, the treatment of cognitive and / or neurobehavioral disorders is by inhibition of oxidative stress and prostaglandin E2 synthesis. In some embodiments, the treatment of cognitive and / or neurobehavioral disorders is by inhibition of oxidative stress and microsomal prostaglandin E synthase 1.

[0024] In some embodiments, the companion animal exhibits symptoms including behavioral changes selected from appetite, drinking behavior, vocalization, elimination behavior, sleep patterns, aimless behavior, adaptive abilities, social behavior, perception, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms including behavioral changes selected from vocalization, elimination behavior, sleep patterns, aimless behavior, social behavior, perception, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms including behavioral changes selected from sleep patterns, social behavior, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms including memory changes. In some embodiments, the companion animal exhibits symptoms including behavioral changes selected from orientation (e.g., staring blankly, getting lost indoors, etc.), memory (e.g., lack of recognition of owner, elimination in inappropriate places, etc.), apathy (e.g., reduced time active, avoidance of owner, etc.), olfactory impairment (e.g., difficulty finding food, etc.), and movement.

[0025] In some embodiments, the companion animal exhibits symptoms including behavioral changes selected from: spatial orientation, social interaction, sleep-wake cycles, and elimination in inappropriate places.

[0026] In some embodiments, the companion animal exhibits a pathophysiological change. In some embodiments, the pathophysiological change is selected from cerebral cortical atrophy, basal ganglia atrophy, increased ventricular size, demyelination, increased glial cell size, increased number of glial cells, loss of neurons, especially in the cortical region above the hippocampus, axonal degeneration, and accumulation of beta-amyloid plaques. In some embodiments, the pathophysiological change is selected from increased glial cell size, increased number of glial cells, loss of neurons, and increased beta-amyloid deposition.

[0027] In some embodiments, the companion animal is selected from cats, chinchillas, dogs, ferrets, gerbils, guinea pigs, hamsters, hedgehogs, mice, rabbits, and rats. In certain preferred embodiments, the companion animal is a cat or a dog. In some embodiments, the companion animal is a canine or feline. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0028] definition The definitions of terms set forth below may apply to the use of a term by itself or in combination with other terms.

[0029] The term "acetoxy" refers to a group represented by the general formula hydrocarbylC(O)O-, preferably alkylC(O)O-.

[0030] The term "acetyl" refers to a group represented by the general formula CH3C(O)-.

[0031] An "alkyl" group (including the "alkyl" of haloalkyl) or "alkane" is a fully saturated straight-chain or branched non-aromatic hydrocarbon. Typically, a straight-chain or branched alkyl group has from 1 to about 20 carbon atoms, preferably from 1 to about 10 carbon atoms, unless otherwise defined. A C1-C6 straight-chain or branched alkyl group is also referred to as a "lower alkyl" group. In some embodiments, an alkyl is a C1-C5 alkyl, more preferably a C1-C3 alkyl. More specifically, preferred alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, and tert-butyl.

[0032] Furthermore, the term "alkyl" (or "lower alkyl"), as used throughout the specification, examples, and claims, is intended to include both "unsubstituted alkyl" and "substituted alkyl," the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents, unless otherwise specified, can include, for example, halogen, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl, e.g., alkyl C(O)), thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, silyl ether, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, or aromatic or heteroaromatic moieties. It will be understood by those of skill in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. For example, the substituents of substituted alkyls can include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonates and phosphinates), sulfonyl (including sulfates, sulfonamides, sulfamoyl, and sulfonates), and silyl groups, as well as ethers, alkylthiols, carbonyls (including ketones, aldehydes, carboxylates, and esters), -CF3, -CN, and the like. Exemplary substituted alkyls are described below. Cycloalkyls may be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, -CF3, -CN, and the like.

[0033] "C x~y The term " when used in conjunction with a chemical moiety, such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy, is intended to include groups containing x to y carbons in the chain. For example, "C x~yThe term "alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups including straight chain alkyl and branched chain alkyl groups containing x to y carbons in the chain, including haloalkyl groups, such as trifluoromethyl and 2,2,2-trifluoroethyl. CO alkyl represents a hydrogen when the group is in a terminal position and a bond when the group is internal. 2~y alkenyl" and "C 2~y The term "alkynyl" refers to substituted or unsubstituted unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one double or triple bond respectively.

[0034] The term "alkanoyl" refers to a group represented by the general formula hydrocarbyl-C(O)-, preferably alkyl-C(O)-.

[0035] The term "alkoxy" (including the "alkoxy" of haloalkoxy) refers to an alkyl group, preferably a lower alkyl group, having an oxygen attached thereto. In some embodiments, preferably, alkoxy is C 1~ C5 alkoxy, more preferably C1-C3 alkoxy. More specifically, preferred alkoxy includes, but is not limited to, methoxy, ethoxy and propaneoxy. Halogen includes, but is not limited to, fluoride, chloride, bromide and iodide. Preferably, alkanoyl is C2-C 10 Alkanoyl, more preferably C3 to C5 alkanoyl. More specifically, preferred alkanoyl includes, but is not limited to, ethanoyl, propanoyl and cyclohexanecarbonyl.

[0036] The terms "amine" and "amino" are art-recognized and refer to both unsubstituted and substituted amines and their salts, e.g.,

[0037] [ka] wherein each R 10 R independently represents a hydrogen or a hydrocarbyl group, or two R10 together with the N atom to which it is attached completes a heterocycle having 4 to 8 atoms in the ring structure.

[0038] The term "aryl" as used herein includes substituted or unsubstituted monocyclic aromatic groups in which each atom of the ring is carbon. Preferably, the ring is a 5-10 membered ring, more preferably a 6-10 membered ring or a 6 membered ring. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are shared between two adjacent rings, at least one of the rings being aromatic, e.g., the other cyclic rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocyclyl. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like. Exemplary substitutions on an aryl group may include, for example, halogen, haloalkyl, such as trifluoromethyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl, such as alkyl C(O)), thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, silyl ether, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamide, sulfonyl, heterocyclyl, aralkyl, or an aromatic or heteroaromatic moiety.

[0039] The terms "halo" and "halogen" as used herein mean halogen and include chloro, fluoro, bromo and iodo.

[0040] The term "lower" when used in conjunction with chemical moieties such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy, is intended to include groups in which there are 10 or fewer non-hydrogen atoms in the substituent, preferably 6 or fewer. "Lower alkyl" refers, for example, to alkyl groups containing 10 or fewer carbon atoms, preferably 6 or fewer. In certain embodiments, the acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents as defined herein are lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, respectively, whether they occur alone or in combination with other substituents, for example in the recitations of hydroxyalkyl and aralkyl (where, for example, atoms in aryl groups are not counted when counting carbon atoms in an alkyl substituent).

[0041] The term "substituted" refers to a moiety having a substituent replacing a hydrogen on one or more carbons of the backbone. It is understood that "substituted" or "substituted with" includes the implicit proviso that such substitution is subject to the permissible valences of the substituted atom and substituent, as well as the implicit proviso that the substitution results in a stable compound that does not spontaneously undergo transformation, e.g., by rearrangement, cyclization, elimination, and the like. As used herein, the term "substituted" is intended to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched or unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. In suitable organic compounds, the permissible substituents can be one or more and can be the same or different. For purposes of this invention, heteroatoms, e.g., nitrogen, can have hydrogen substituents and / or any permissible substituent of organic compounds described herein that satisfies the valence of the heteroatom. The substituents may include any of the substituents described herein, for example, halogen, haloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, or aromatic or heteroaromatic moieties. It will be understood by those of skill in the art that the substituents may themselves be substituted, where appropriate. Unless specifically stated as "unsubstituted," reference to a chemical moiety herein is understood to include substituted variations. For example, reference to an "aryl" group or moiety implicitly includes both substituted and unsubstituted variations.

[0042] The term "pharmaceutically acceptable salt" of the present disclosure refers to a salt formed by a non-toxic or low-toxicity acid or base. When the compound of the present disclosure is acidic, a base addition salt of the compound of the present disclosure can be prepared by reacting the free base of the compound with a sufficient amount of the desired base and a suitable inert solvent. Pharmaceutically acceptable base addition salts include, but are not limited to, salts prepared with sodium, potassium, calcium, ammonium, magnesium or organic amino. When the compound of the present disclosure is basic, an acid addition salt of the compound can be prepared by reacting the free base of the compound with a sufficient amount of the desired acid and a suitable inert solvent. Pharmaceutically acceptable acid addition salts include, but are not limited to, propionic, isobutyric, oxalic, malic, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, hydrochloric, bromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphate, dihydrogenphosphate, sulfuric, monohydrogensulfuric, hydroiodic, and phosphorous. Additionally, pharmaceutically acceptable salts of the present disclosure include, but are not limited to, salts of amino acids such as arginates, and analogs of organic acids such as glucuronic or galacturonic acid.

[0043] For example, a pharma- ceutically acceptable salt of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid (Compound 2), which is one preferred example of the present disclosure, can be prepared according to the following reaction scheme 1. However, the following reaction scheme is provided for illustrative purposes and is not intended to limit the scope of the present disclosure.

[0044] <Reaction Scheme 1>

[0045] [ka]

[0046] In Scheme 1, M is a pharma- ceutically acceptable metal or basic organic compound, such as diethylamine, lithium, sodium, and potassium.

[0047] More specifically, diethylamine salts can be prepared by dissolving the compound in alcohol, adding diethylamine dropwise, stirring the mixture, distilling under vacuum, and crystallizing the residue by adding ether. Alkali metal salts can be made by preparing the desired salt with inorganic reagents such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc. in a solvent such as alcohol, acetone, acetonitrile, etc., and then lyophilizing. Furthermore, following a similar method, lithium salts can be made with lithium acetate, sodium salts can be made with sodium 2-ethylhexanoate or sodium acetate, and potassium salts can be made with potassium acetate.

[0048] Some of the compounds of the present disclosure may be in hydrated form, and may exist as solvated or nonsolvated forms. Some of the compounds according to the present disclosure may exist as crystalline or amorphous forms, and any physical form is included within the scope of the present disclosure. Furthermore, some of the compounds of the present disclosure may contain one or more asymmetric carbon atoms or double bonds, and therefore exist in two or more stereoisomeric forms, such as racemates, enantiomers, diastereomers, geometric isomers, etc. The present disclosure includes these individual stereoisomers of the compounds.

[0049] composition The present disclosure also provides a composition comprising the 5-benzylaminosalicylic acid derivative represented by the above formula (I) or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient or additive. The 5-benzylaminosalicylic acid derivative represented by the above formula (I) or a pharma- ceutically acceptable salt thereof of the present disclosure may be administered alone. In some embodiments, the composition comprising the compound of formula (I) is administered together with any convenient carrier, diluent, etc.

[0050] In some embodiments, the composition comprises about 1 mg to about 1,000 mg of a compound of formula (I). In some embodiments, the composition comprises about 10 mg to about 1,000 mg of a compound of formula (I). In some embodiments, the composition comprises about 1 mg to about 500 mg of a compound of formula (I). In some embodiments, the composition comprises about 1 mg to about 100 mg of a compound of formula (I). In some embodiments, the composition comprises about 2 mg to about 50 mg of a compound of formula (I).

[0051] In some embodiments, the formulation for administration may be a single dose unit or a multiple dose unit. In some embodiments, the composition comprises a single dose unit. In some embodiments, the composition comprises a multiple dose unit.

[0052] The compositions for oral administration of the present disclosure may be formulated in solid or liquid form. Solid formulations include, but are not limited to, powders, granules, tablets, capsules, suppositories, and the like. Solid formulations may also include, but are not limited to, diluents, flavorings, binders, preservatives, disintegrants, lubricants, fillers, plasticizers, and the like. Liquid formulations include, but are not limited to, solutions, such as aqueous solutions and propylene glycol solutions, suspensions, emulsions, and the like, and may be prepared by adding suitable additives, such as colorants, flavorings, stabilizers, thickeners, and the like. In some embodiments, the compositions are administered in a form selected from capsules, tablets, powders, and solutions. In some embodiments, the compositions are administered by mixing with a dietary supplement. In some embodiments, the compositions are administered as a dietary supplement. In some embodiments, the compositions are administered by mixing with food. In some embodiments, the compositions are administered as a food composition. In some embodiments, the compositions are administered by dissolving in water. In some embodiments, the compositions are administered as a capsule with water. In some embodiments, the compositions are administered as a chewable tablet.

[0053] For example, powders can be made by simply mixing the 5-benzylaminosalicylic acid derivatives of the present disclosure and pharma- ceutically acceptable excipients, such as lactose, starch, microcrystalline cellulose, etc. Granules can be prepared by mixing the compound and pharma- ceutically acceptable excipients. In some embodiments, the pharma- ceutically acceptable excipients include diluents and / or pharma- ceutically acceptable binders. In some embodiments, the binders are polyvinylpyrrolidone, hydroxypropyl cellulose, etc.

[0054] In some embodiments, the composition is formed by wet granulation using a suitable solvent such as water, ethanol, isopropanol, etc. In some embodiments, the composition is formed by direct compression using a compression force. Additionally, tablets can be made by mixing the granules with a pharma- ceutically acceptable lubricant, such as magnesium stearate, and tableting the mixture.

[0055] The pharmaceutical composition of the present disclosure may be administered in the form of, but not limited to, oral preparations, injection preparations (e.g., intramuscular, intraperitoneal, intravenous, drip, subcutaneous, implant), inhalation, intranasal, intravaginal, intrarectal, sublingual, transdermal, topical, etc., depending on the disorder to be treated and the condition of the animal. The composition of the present disclosure may be formulated in a suitable dosage unit containing non-toxic pharmaceutically acceptable carriers, additives and / or vehicles, all of which are commonly used in the art, depending on the route of administration. Depot-type preparations that can continuously release drugs for a desired period of time are also included within the scope of the present disclosure.

[0056] In some embodiments, the composition comprises: About 1 mg to about 1000 mg of a compound of formula (I), about 50% w / w to about 70% w / w of lactose monohydrate, about 2% w / w to about 8% w / w of croscarmellose sodium, about 0.1% w / w to about 1% w / w of magnesium stearate, and About 0.1% w / w to about 2% w / w sodium lauryl sulfate A capsule comprising:

[0057] In some embodiments, the composition comprises: About 1 mg to about 1000 mg of a compound of formula (I), Approximately 60% w / w lactose monohydrate, Croscarmellose sodium at about 5% w / w, About 0.5% w / w magnesium stearate, and Approximately 1% w / w sodium lauryl sulfate A capsule comprising:

[0058] In some embodiments, the composition comprises: About 1 mg to about 1000 mg of a compound of formula (I), about 30% w / w to about 50% w / w of starch, About 15% w / w to about 25% w / w crude protein, About 10% w / w to about 20% crude fat, from about 0.1% w / w to about 5% w / w of crude fiber; Crude ash content of about 1% w / w to about 10% w / w, about 0.1% w / w to about 5% w / w arginine, about 0.1% w / w to about 2.5% w / w of calcium, about 0.1% w / w to about 3% w / w of lysine, About 0.1% w / w to about 3% w / w of methionine and cystine, and About 0.1% w / w to about 2.5% w / w of phosphorus A food composition comprising:

[0059] In some embodiments, the composition comprises: About 1 mg to about 1000 mg of a compound of formula (I), about 42.7% w / w starch, Approximately 21.0% w / w crude protein; Approximately 14% w / w crude fat, Approximately 1.9% w / w crude fiber; Crude ash content of about 6.1% w / w; Arginine at about 1.4% w / w, Approximately 0.75% w / w calcium, about 1.1% w / w lysine, About 1.18% w / w methionine and cystine, and Approximately 0.5% w / w phosphorus A food composition comprising:

[0060] In some embodiments, the composition comprises: About 1 mg to about 1000 mg of a compound of formula (I), About 5% w / w to about 20% w / w crude protein, About 0.1% w / w to about 5% w / w crude fat, from about 0.1% w / w to about 5% w / w of crude fiber; A crude ash content of about 0.1% w / w to about 5% w / w, about 0% w / w to about 1% w / w of calcium, about 0% w / w to about 2% w / w of potassium, and Approximately 60% w / w to approximately 95% w / w of water It is a dietary supplement containing.

[0061] In some embodiments, the composition comprises: About 1 mg to about 1000 mg of a compound of formula (I), Approximately 12.0% w / w crude protein; Approximately 1.5% w / w crude fat, Approximately 0.4% w / w crude fiber; Crude ash content of about 1.5% w / w; Approximately 0.02% w / w calcium, About 0.1% w / w potassium, and Approximately 78.0% w / w water It is a dietary supplement containing.

[0062] In some embodiments, the composition comprises: About 1 mg to about 1000 mg of a compound of formula (I), about 0.1% w / w to about 5% w / w of silicon dioxide; about 0% w / w to about 2% w / w of benzoic acid, about 0% w / w to about 1% w / w of sorbic acid, about 0.1% w / w to about 10% w / w of magnesium stearate, about 10% w / w to about 30% w / w of cellulose; about 30% w / w to about 50% w / w of a chicken meat source; about 0.1% w / w to about 5% w / w of dry yeast, and About 10% w / w to about 30% w / w of glucose It is a chewable tablet comprising:

[0063] In some embodiments, the composition comprises: About 1 mg to about 1000 mg of a compound of formula (I), about 3% w / w silicon dioxide, Benzoic acid at about 0.05% w / w, about 0.01% w / w sorbic acid, about 5% w / w magnesium stearate, Approximately 20% w / w cellulose, Approximately 40% w / w chicken powder, About 3% w / w dry yeast, and Approximately 19% w / w glucose It is a chewable tablet comprising:

[0064] The present disclosure also provides the use of 5-benzylaminosalicylic acid derivatives or pharma- ceutically acceptable salts thereof for the treatment of cognitive decline in animals. That is, the present disclosure provides a pharmaceutical composition for the treatment of cognitive decline in animals, comprising 5-benzylaminosalicylic acid derivatives or pharma- ceutically acceptable salts thereof represented by the above chemical formula (I). More specifically, 5-benzylaminosalicylic acid derivatives or pharma- ceutically acceptable salts thereof can be used for the treatment of cognitive decline in animals, including cognitive dysfunction syndrome (e.g., canine cognitive dysfunction syndrome), dysthymia, regressive depression, and confusion syndrome. In some embodiments, the cognitive decline is caused by CDS.

[0065] In some embodiments, the composition is used in the manufacture of a medicament for the treatment of companion animal cognitive dysfunction syndrome (CDS). In some embodiments, the composition is used in the manufacture of a medicament for treating CDS by simultaneous pharmacological inhibition of oxidative stress and inflammation. In some embodiments, the composition is used in the manufacture of a medicament for treating CDS by inhibition of oxidative stress and prostaglandin E2 synthesis. In some embodiments, the composition is used in the manufacture of a medicament for treating CDS by inhibition of oxidative stress and microsomal prostaglandin E synthase 1. However, the use of 5-benzylaminosalicylic acid derivatives or pharmaceutically acceptable salts thereof according to the present disclosure is not limited to the above specific disease names.

[0066] The present disclosure provides the use of 5-benzylaminosalicylic acid derivatives or pharma- tically acceptable salts thereof for the preparation of pharmaceutical products for treating cognitive and / or neurobehavioral disorders in companion animals, such as canines or felines, for example, reducing or inhibiting decline in social interaction, reducing age-related behavioral changes, increasing trainability, improving attention, maintaining brain function health, reducing memory loss, and treating cognitive decline. In some embodiments, the companion animal exhibits symptoms including behavioral changes selected from appetite, drinking behavior, vocalization, excretion behavior, sleep patterns, aimless behavior, adaptive ability, social behavior, perception, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms including behavioral changes selected from vocalization, excretion behavior, sleep patterns, aimless behavior, social behavior, perception, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms including behavioral changes selected from sleep patterns, social behavior, disorientation, and memory. In some embodiments, the companion animal exhibits symptoms including memory changes, hi some embodiments, the companion animal exhibits symptoms including behavioral changes selected from orientation (e.g., blank staring, getting lost indoors, etc.), memory (e.g., lack of recognition of owner, defecation in inappropriate places, etc.), apathy (e.g., reduced time spent on activities, avoidance of contact with owner, etc.), olfactory impairment (e.g., difficulty finding food, etc.), and movement.

[0067] In some embodiments, the companion animal exhibits symptoms including behavioral changes selected from: spatial orientation, social interaction, sleep-wake cycles, and elimination in inappropriate places.

[0068] In some embodiments, the companion animal exhibits a pathophysiological change. In some embodiments, the pathophysiological change is selected from cerebral cortical atrophy, basal ganglia atrophy, increased ventricular size, demyelination, increased glial cell size, increased number of glial cells, loss of neurons, especially in the cortical region above the hippocampus, axonal degeneration, and accumulation of beta-amyloid plaques. In some embodiments, the pathophysiological change is selected from increased glial cell size, increased number of glial cells, loss of neurons, and increased beta-amyloid deposition.

[0069] To treat cognitive decline in feline companion animals, the compounds of the present disclosure may be administered daily at a dose of about 0.01 mg / kg to about 200 mg / kg, preferably about 0.1 mg / kg to about 30 mg / kg. In some embodiments, the compounds of formula (I) are administered at a dose of about 0.1 mg / kilogram to about 10 mg / kilogram of body weight. However, the dosage may vary depending on the condition of the animal (age, sex, weight, etc.), the severity of the disease of the animal in need thereof, the active ingredient used, the diet, etc. The compounds of the present disclosure may be administered once a day, or several times a day in divided doses as needed. In some embodiments, the compounds of formula (I) are administered once, twice, or three times a day. In some embodiments, the compounds of formula (I) are administered once a day.

[0070] [Example] Compound 2, 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)ethylamino]benzoic acid, is used as a representative compound. Hereinafter, the present disclosure will be described in detail to help those skilled in the art understand the present disclosure. However, the following examples are provided for illustrative purposes and are not intended to limit the scope of the present disclosure. It is clear that various modifications may be made without departing from the spirit and scope of the present disclosure or sacrificing all of its important advantages.

[0071] 1. Study design and subjects Preliminary data showed maximal beneficial effects, including improved cognitive and motor function, following oral administration of Compound 2 at a dose of 2.5 mg / kg in animal models of AD (APP / PS1 mice) and amyotrophic lateral sclerosis (G93A mice).

[0072] After oral administration of compound 2 at a dose of 2.5 mg / kg in mice, max The mean maximum plasma concentration and AUC (area under the plasma level curve) were determined to be 5.19±0.96 μg / mL and 9.61±1.38 μg h / mL, respectively.

[0073] The potential systemic toxicity of Compound 2 in beagle dogs was investigated at Huntington Life Science, a large non-clinical contract research organization in Cambridgeshire, UK. Three groups, each containing three males and three females, were given Compound 2 at doses of 20, 65 or 200 mg / kg / day for 13 weeks. Daily oral administration of Compound 2 to beagle dogs resulted in adaptive changes in the liver and kidney, as well as secondary findings in the thyroid gland. There was no evidence of toxicity, although treated animals tended to resist at the time of dose administration. All major treatment-related findings showed at least partial recovery during the 4-week recovery period, with most showing complete recovery. Therefore, 200 mg / kg / day was considered to be the no observed adverse effect level (NOAEL) in dogs.

[0074] In a pharmacokinetic study, C max and AUC were 10.6 μg / mL and 75.1 μg h / mL, respectively, following oral administration of 20 mg / kg / day of Compound 2. Based on the safety and pharmacokinetic profile of Compound 2, a dose of 10 mg / kg / day was selected to investigate the safety and efficacy of Compound 2 in canine CDS.

[0075] In stability tests, Compound 2 was stable for at least 60 months at 25° C. Additionally, capsule and chewable formulations of Compound 2 were stable for at least 24 and 12 months, respectively, at 25° C.

[0076] The companion animals tested in the study were 22 elderly dogs (12-19 years old) diagnosed with CDS. The subjects of the example are shown in Table 1. Each dog that participated in the study met the following criteria: weight <12 kg (regardless of sex), dogs that had lived with their owners for at least 90 days, dogs that could take oral medication, dogs that were diagnosed with CDS by the examiner (Canine Cognitive Dysfunction Rating (CCDR) scale ≥ 50 points), and dogs for which informed consent was obtained by the owner. Pregnant or lactating dogs that were hypersensitive to salicylic acid derivatives or had underlying diseases (i.e. renal insufficiency, vision impairment, heart failure or renal failure) were excluded. In addition, dogs that had participated in any other clinical trials within 90 days or dogs with other neurodegenerative diseases in addition to CDS were excluded.

[0077] This study was a randomized, blinded, placebo-controlled clinical trial to investigate the efficacy and safety of Compound 2 in dogs affected by CDS. Two questionnaires, the CCDR scale and the Canine Dementia Scale (CADES), were assessed to investigate the efficacy of Compound 2. To measure the safety of Compound 2, the dogs' vital signs, physical examination, and blood tests were also performed, as well as investigating the occurrence of adverse events. Compound 2 was prescribed for oral administration at a dose of 10 mg / kg once daily for 8 weeks. Subjects 3 and 4 were given Compound 2 for an additional 4 weeks with the approval of the study director. Instead of Compound 2, subjects 18-22 were given a placebo for 8 weeks. In this study, dogs were given Compound 2 in various ways: mixed with dietary supplements (subjects 1 and 3), mixed with food (subjects 2 and 6), dissolved in water (subject 4), or capsules and water (subject 5), or chewable tablets and water (subjects 7-22).

[0078] [Table 1]

[0079] 2. Questionnaire for dogs with CDS Rating scales are essential tools for CDS diagnosis, staging, evaluation and careful monitoring of disease symptoms, as well as for evaluating the effectiveness of treatment strategies. Over the last decade, several rating scales have been developed, such as the CCDR scale [21-24]. To evaluate the severity of CDS in this study, two questionnaires (CCDR scale and CADES) were administered before and after oral administration of Compound 2 by veterinarians. The questionnaires include a wide range of items measuring appetite, drinking behavior, roaring, excretion behavior, daytime / nighttime sleep patterns, aimless behavior, adaptive ability, social behavior, perception, disorientation, and memory.

[0080] 2.1 Testing using the CCDR scale The CCDR scale consists of 13 items based on CDS symptoms (Table 2). The 13 behaviors included various problems related to orientation (staring blankly, getting lost indoors), memory (lack of recognition of the owner, defecation in inappropriate places), apathy (reduced time spent active, avoiding contact with the owner), olfactory impairment (difficulty finding food), and movement. These problems deteriorate both the dog's quality of life and the bond between the dog and the owner [25, 26]. A score of ≥ 50 on the CCDR indicates CDS in older dogs (12-19 years old). In this study, CCDR scores before and after administration of Compound 2 in dogs with CDS were compared.

[0081] [Table 2]

[0082] A total of 22 companion dogs with CDS were started in the study, 17 of which received 8 weeks of treatment with Compound 2, and subjects 1 and 2 developed age-dependent nephrotoxicity and died naturally 7 weeks after treatment. Even 4 weeks after oral administration of Compound 2, most companion dogs with CDS showed a significant reduction in behavioral trends on the CCDR scale, suggesting that dogs treated with Compound 2 showed near-normal cognitive function within 4 weeks (Table 3). In addition, the frequency of abnormal behaviors was reduced and social interactions improved in most of the dogs. Improvement in CCDR scores after administration of Compound 2 was observed up to 8 weeks.

[0083] [Table 3]

[0084] To determine whether the beneficial effects of compound 2 can be maintained after the cessation of drug treatment, a follow-up study was conducted in six companion dogs. In subjects 3, 4, 7, 8, 10 and 11 who received 8 or 12 weeks of treatment with compound 2, the beneficial effects of compound 2 were observed for 4 or 8 weeks after the last administration of the drug (Tables 4 and 5). Importantly, social interaction, proper elimination, and changes in sleep-wake activity cycle were significantly improved. This suggests that compound 2 can be applied to treat CDS by improving cognitive deficits and inhibiting disease progression.

[0085] [Table 4]

[0086] [Table 5]

[0087] 2.2 CADES Inspection To ensure and validate the CCDR scale, an additional questionnaire, CADES, was used, which includes 17 items distributed in four domains related to changes in dog behavior: spatial orientation, social interaction, sleep-wake cycle and inappropriate defecation (Table 6) [3]. It can be classified according to the different stages of cognitive impairment: mild, moderate and severe cognitive impairment. CADES is also known to be suitable for the longitudinal assessment of the progression of cognitive impairment in canines and potentially as a readout of the efficacy of treatments.

[0088] [Table 6]

[0089] The spatial orientation scores and variances are shown in Table 7. After 4 weeks of administration, 10 of 17 (59%) companion dogs showed improvement in spatial disorientation. Subjects 3, 4 and 10 showed near-normal performance in spatial orientation items. Beneficial effects were observed in 9 of 15 (60%) companion dogs after 8 weeks of oral administration of Compound 2. Overall, these results indicate that Compound 2 improves the spatial orientation abilities of dogs with CDS.

[0090] [Table 7]

[0091] The social interaction scores in CADES are shown in Table 8. Four weeks after administration of Compound 2, most of the participating dogs showed a significant improvement in social interaction, except for subjects 5, 8, 11, 12, 14, and 17. Three dogs (subjects 3, 4, and 10) showed severely abnormal social behavior before treatment with Compound 2, but their social behavior was similar to that of normal aged dogs four weeks after treatment. Furthermore, most dogs showed an improvement in social activity eight weeks after treatment with Compound 2. More importantly, eight of 15 (53%) companion dogs showed a further improvement in social interaction eight weeks after administration of Compound 2 compared to the improvement four weeks after administration of Compound 2. Overall, these results indicate that Compound 2 improves social interaction activity in dogs affected by CDS.

[0092] [Table 8]

[0093] The changes in the sleep-wake cycle in CADES are quantified in Table 9. Before administration of Compound 2, all dogs except subject 14 had severe abnormal behaviors in terms of the sleep-wake cycle (item 11), but 10 of 15 (67%) companion dogs were significantly improved 8 weeks after administration of Compound 2. Meanwhile, a switch from insomnia to hypersomnia (item 12) was observed in 14 of 17 (82%) companion dogs, but the abnormal changes almost disappeared after administration of Compound 2.

[0094] [Table 9]

[0095] The frequency of inappropriate defecation behavior is shown in Table 10. Eight weeks after administration of Compound 2, inappropriate defecation behavior was reduced in all subjects except for subjects 4, 12, 13, and 17. In particular, subjects 3, 5, and 10 did not exhibit inappropriate defecation behavior eight weeks after administration of Compound 2.

[0096] [Table 10]

[0097] The total CADES scores are shown in Table 11. The scores revealed that cognitive dysfunction behavior in all companion dogs with CDS except subject 9 gradually decreased after administration of Compound 2. After 8 weeks of oral administration of Compound 2, significant improvement of cognitive function from severe to moderate, mild, or normal levels was observed.

[0098] [Table 11]

[0099] The beneficial effects of Compound 2 in six companion dogs (subjects 3, 4, 7, 8, 10 and 11) were observed for 4 or 8 weeks after administration was discontinued (Tables 12 and 13). Sleep patterns, inappropriate defecation, social interaction and behavioral activity were significantly improved after treatment with Compound 2. Subjects also became more obedient to their owners and showed reduced aggression. These results suggest that Compound 2 can be administered to reduce cognitive impairment and inhibit disease progression in canine CDS.

[0100] [Table 12]

[0101] [Table 13]

[0102] 2.3 CCDR and CADES results in placebo-fed dogs To clarify the effect of Compound 2 on cognitive impairment, five dogs with CDS (subjects 18-22) were given a placebo. The CCDR and CADES scores in most dogs given placebo did not show significant changes or increases after 8 weeks of placebo treatment, indicating that placebo treatment did not affect cognitive function. Overall, it is strongly implied that Compound 2 can be administered to reduce cognitive impairment in canine CDS.

[0103] [Table 14]

[0104] [Table 15]

[0105] 3. Safety evaluation in dogs with CDS During this study, the safety of Compound 2 in dogs with CDS was evaluated at each visit. As a result, no significant changes were observed in blood toxicity tests, and no treatment-related adverse events occurred.

[0106] 4. Conclusion Two questionnaires were used to evaluate the effect of Compound 2 on cognitive function in companion dogs with CDS. In the CCDR scale, administration of Compound 2 substantially improved cognitive function to near-normal scores. Consistent with the CCDR scale, the severe cognitive and neurobehavioral disorders in dogs with CDS were significantly alleviated within 8 weeks after administration of Compound 2. These beneficial effects were maintained for 4 or 8 weeks after the completion of 8 or 12 weeks of administration of Compound 2. In addition, no adverse events or toxicity were observed during the study. Meanwhile, no significant improvement was observed in the placebo group. Taken together, these findings strongly suggest that Compound 2 can be applied to treat canine and even feline CDS. [Industrial Applicability]

[0107] The present disclosure provides compositions comprising Compound 2 for treating cognitive and neurobehavioral deficits in neurological disorders including CDS, dysthymia, regressive depression and confusion syndrome in canines or felines, and methods of administering a therapeutically effective amount of Compound 2. The compositions and methods of the disclosure are highly useful for reducing or inhibiting cognitive and neurobehavioral deficits in age-related neurological disorders in canines or felines.

[0108] Other publications 1. Azkona, G., et al., Prevalence and risk factors of behavioral changes associated with age-related cognitive impairment in geriatric dogs. J Small Anim Pract, 2009. 50(2): p. 87-91. 2. Neilson, JC, et al., Prevalence of behavioral changes associated with age-related cognitive impairment in dogs. J Am Vet Med Assoc, 2001. 218(11): p. 1787-91. 3. Madari, A., et al., Assessment of severity and progression of canine cognitive dysfunction syndrome using the CAnine DEmentia Scale (CADES). Appl Anim Behav Sci., 2015. 171: p. 138-45. 4. Salvin, HE, et al., Under diagnosis of canine cognitive dysfunction: a cross-sectional survey of older companion dogs. The Veterinary Journal, 2010. 184(3): p. 277-281. 5. Hart, B.L. and L.A. Hart, Selecting, raising, and caring for dogs to avoid problem aggression. Journal of the American Veterinary Medical Association, 1997. 210(8): p. 1129. 6. Landsberg, G.M., J. Nichol, and J.A. Araujo, Cognitive dysfunction syndrome: a disease of canine and feline brain aging. Vet Clin North Am Small Anim Pract, 2012. 42(4): p. 749-68, vii. 7. Landsberg, G.M., T. Deporter, and J.A. Araujo, Clinical signs and management of anxiety, sleeplessness, and cognitive dysfunction in the senior pet. Vet Clin North Am Small Anim Pract, 2011. 41(3): p. 565-90. 8. Gonzalez-Martinez, A., et al., Effect of age and severity of cognitive dysfunction on two simple tasks in pet dogs. Vet J, 2013. 198(1): p. 176-81. 9. Cummings, B.J., et al., β-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiology of learning and memory, 1996. 66(1): p. 11-23. 10. Cummings, B.J., et al., β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiology of aging, 1996. 17(6): p. 921-933. 11. Cummings, B.J., et al., Diffuse plaques contain C-terminal Aβ42 and not Aβ40: evidence from cats and dogs. Neurobiology of aging, 1996. 17(4): p. 653-659. 12. Ozawa, M., et al., The Relation between canine cognitive dysfunction and age-related brain lesions. J Vet Med Sci, 2016. 78(6): p. 997-1006. 13. Rofina, J., et al., Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. Brain research, 2006. 1069(1): p. 216-226. 14. Head, E., et al., Visual-discrimination learning ability and β-amyloid accumulation in the dog. Neurobiology of aging, 1998. 19(5): p. 415-425. 15. Tapp, P.D., et al., Frontal lobe volume, function, and β-amyloid pathology in a canine model of aging. Journal of Neuroscience, 2004. 24(38): p. 8205-8213. 16. Druce, K., Canine cognitive dysfunction-recognition and treatment. Veterinary Nursing Journal, 2014. 29(8): p. 268-270. 17. Ruehl, W., et al., Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy, in Progress in Brain Research. 1995, Elsevier. p. 217-225. 18. Head, E., et al., Spatial learning and memory as a function of age in the dog. Behavioral neuroscience, 1995. 109(5): p. 851. 19. Campbell, S., A. Trettien, and B. Kozan, A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting. Vet Ther, 2001. 2(1): p. 24-39. 20. Shin, J.H., et al., Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. Journal of neurochemistry, 2012. 122(5): p. 952-961. 21. Colle, M.A., et al., Vascular and parenchymal Abeta deposition in the aging dog: correlation with behavior. Neurobiol Aging, 2000. 21(5): p. 695-704. 22. Pugliese, M., et al., Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia. Prog Neuropsychopharmacol Biol Psychiatry, 2005. 29(4): p. 603-10. 23. Schneider, B.M. and M.H. Erhard, [Canine cognitive dysfunction syndrome: prevalence, diagnosis and therapeutic measures]. Tierarztl Prax Ausg K Kleintiere Heimtiere, 2010. 38(2): p. 113-8. 24. Salvin, HE, et al., The canine cognitive dysfunction rating scale (CCDR): a data-driven and ecologically relevant assessment tool. Vet J, 2011. 188(3): p. 331-6. 25. Hughes, CP, et al., A new clinical scale for the staging of dementia. Br J Psychiatry, 1982. 140: p. 566-72. 26. Swan, GE and D. Carmelli, Impaired olfaction predicts cognitive decline in nondemented older adults. Neuroepidemiology, 2002. 21(2): p. 58-67. (Additional Note) [Appendix 1] Formula (I): [ka] (In the formula, X is CO, SO2 and (CH2) n is selected from R1 is selected from hydrogen, C1-C6 alkyl and C1-C6 alkanoyl; R2 is selected from hydrogen and C1-C6 alkyl; R3 is selected from hydrogen and a C1-C5 acetyl group; R4 is selected from a phenyl group, a phenoxy group, and a 5-10 membered aryl group unsubstituted or substituted with one or more of the group consisting of nitro, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C5 alkoxy, and C1-C5 haloalkoxy; n is an integer from 1 to 5, inclusive; or a pharma- ceutically acceptable salt thereof, For example, a composition comprising a pharma- ceutically acceptable excipient suitable for oral administration. [Appendix 2] The compound of formula (I) is 2-hydroxy-5-phenethylamino-benzoic acid, 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 2-hydroxy-5-[2-(3-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 5-[2-(3,5-bis-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-[2-(2-nitro-phenyl)-ethylamino]-benzoic acid, 5-[2-(4-chloro-phenyl)-ethylamino]-benzoic acid, Amino]-2-hydroxy-benzoic acid, 5-[2-(3,4-difluoro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(2-fluoro-4-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-[2-(4-methoxy-phenyl)- ethylamino]-benzoic acid, 2-hydroxy-5-(2-o-tolyl-ethylamino)-benzoic acid, 2-hydroxy-5-(3-phenyl-propylamino)-benzoic acid, 2-hydroxy-5-[3-(4-trifluoromethyl-phenyl)-propylamino]-benzoic acid, 5-[3-(4-fluoro-phenyl)-propylamino]-2-hydroxy-benzoic acid, 5-[3-(3,4-dichloro-phenyl)-propylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-(3-p-tolyl-propylamino) -benzoic acid, 2-acetoxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 5-[2-(2-chloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-benzylaminosalicylic acid, 5-(4-nitrobenzyl)aminosalicylic acid, 5-(4-chlorobenzyl)aminosalicylic acid, 5-(4-trifluoromethylbenzyl)aminosalicylic acid, 5-(4-fluorobenzyl)aminosalicylic acid, 5-(4-methoxybenzyl)aminosalicylic acid, 5-(2,3,4,5,The composition according to claim 1, wherein the 5-(4-nitrobenzyl)aminosalicylic acid is selected from the group consisting of 6-pentafluorobenzyl)aminosalicylic acid, 5-(4-nitrobenzyl)amino-2-hydroxyethyl benzoate, 5-(4-nitrobenzyl)-N-acetylamino-2-hydroxyethyl benzoate, 5-(4-nitrobenzyl)-N-acetylamino-2-acetoxyethyl benzoate, 5-(4-nitrobenzoyl)aminosalicylic acid, 5-(4-nitrobenzenesulfonyl)aminosalicylic acid, 5-[2-(4-nitrophenyl)-ethyl]aminosalicylic acid, and 5-[3-(4-nitro-phenyl)-n-propyl]aminosalicylic acid. [Appendix 3] The composition according to claim 2, wherein the compound of formula (I) is 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid. [Appendix 4] 4. The composition according to any one of claims 1 to 3, comprising 1 mg to 1000 mg of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. [Appendix 5] 1 mg to 1000 mg of a compound of formula (I), 60% w / w lactose monohydrate, 5% w / w croscarmellose sodium, 0.5% w / w magnesium stearate, and 1% w / w sodium lauryl sulfate 5. The composition of any one of claims 1 to 4, which is a capsule comprising: [Appendix 6] 1 mg to 1000 mg of a compound of formula (I), 42.7% w / w starch, 21.0% w / w crude protein; 14% w / w crude fat, 1.9% w / w crude fiber; Crude ash content of 6.1% w / w; 1.4% w / w arginine, 0.75% w / w calcium, 1.1% w / w lysine, 1.18% w / w methionine and cystine, and 0.5% w / w phosphorus The composition according to any one of claims 1 to 4, which is a food composition comprising: [Appendix 7] 1 mg to 1000 mg of a compound of formula (I), 12.0% w / w crude protein; 1.5% w / w crude fat, 0.4% w / w crude fiber; Crude ash content of 1.5% w / w; 0.02% w / w calcium, 0.1% w / w potassium, and 78.0% w / w water 5. The composition of any one of claims 1 to 4, which is a dietary supplement comprising: [Appendix 8] 1 mg to 1000 mg of a compound of formula (I), 3% w / w of silicon dioxide, 0.05% w / w benzoic acid, 0.01% w / w sorbic acid, 5% w / w magnesium stearate, 20% w / w of cellulose, 40% w / w chicken source; 3% w / w dry yeast, and 19% w / w glucose 5. The composition of any one of claims 1 to 4, which is a chewable tablet comprising: [Appendix 9] Use of a composition according to any one of claims 1 to 8 for the manufacture of a medicament for the treatment of cognitive dysfunction syndrome (CDS) by simultaneous pharmacological inhibition of oxidative stress and inflammation. [Appendix 10] Use of a compound according to any one of claims 1 to 8 for the manufacture of a medicament for the treatment of CDS by inhibition of oxidative stress and prostaglandin E2 synthesis. [Appendix 11] Use of a compound according to any one of claims 1 to 8 for the manufacture of a medicament for the treatment of CDS by inhibition of oxidative stress and microsomal prostaglandin E synthase 1. [Appendix 12] A method for treating cognitive and / or neurobehavioral disorders, e.g., in a neurological disease, comprising administering to a companion animal in need thereof a compound of formula (I): [ka] (In the formula, X is CO, SO2 and (CH2) n is selected from R1 is selected from hydrogen, C1-C6 alkyl and C1-C6 alkanoyl; R2 is selected from hydrogen and C1-C6 alkyl; R3 is selected from hydrogen and a C1-C5 acetyl group; R4 is selected from a phenyl group, a phenoxy group, and a 5-10 membered aryl group unsubstituted or substituted with one or more of the group consisting of nitro, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C5 alkoxy, and C1-C5 haloalkoxy; n is an integer from 1 to 5, inclusive; or a pharma- ceutically acceptable salt thereof. [Appendix 13] The compound of formula (I) is 2-hydroxy-5-phenethylamino-benzoic acid, 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 2-hydroxy-5-[2-(3-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 5-[2-(3,5-bis-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-[2-(2-nitro-phenyl)-ethylamino]-benzoic acid, 5-[2-(4-chloro-phenyl)-ethylamino]-benzoic acid, Amino]-2-hydroxy-benzoic acid, 5-[2-(3,4-difluoro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(3,4-dichloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(4-fluoro-2-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-[2-(2-fluoro-4-trifluoromethyl-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-[2-(4-methoxy-phenyl)- ethylamino]-benzoic acid, 2-hydroxy-5-(2-o-tolyl-ethylamino)-benzoic acid, 2-hydroxy-5-(3-phenyl-propylamino)-benzoic acid, 2-hydroxy-5-[3-(4-trifluoromethyl-phenyl)-propylamino]-benzoic acid, 5-[3-(4-fluoro-phenyl)-propylamino]-2-hydroxy-benzoic acid, 5-[3-(3,4-dichloro-phenyl)-propylamino]-2-hydroxy-benzoic acid, 2-hydroxy-5-(3-p-tolyl-propylamino) -benzoic acid, 2-acetoxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 5-[2-(2-chloro-phenyl)-ethylamino]-2-hydroxy-benzoic acid, 5-benzylaminosalicylic acid, 5-(4-nitrobenzyl)aminosalicylic acid, 5-(4-chlorobenzyl)aminosalicylic acid, 5-(4-trifluoromethylbenzyl)aminosalicylic acid, 5-(4-fluorobenzyl)aminosalicylic acid, 5-(4-methoxybenzyl)aminosalicylic acid, 5-(2,3,4,5,13. The method of claim 12, wherein the hydroxyl group is selected from the group consisting of 5-(4-nitrobenzyl)aminosalicylic acid, 5-(4-nitrobenzyl)amino-2-hydroxyethyl benzoate, 5-(4-nitrobenzyl)-N-acetylamino-2-hydroxyethyl benzoate, 5-(4-nitrobenzyl)-N-acetylamino-2-acetoxyethyl benzoate, 5-(4-nitrobenzoyl)aminosalicylic acid, 5-(4-nitrobenzenesulfonyl)aminosalicylic acid, 5-[2-(4-nitrophenyl)-ethyl]aminosalicylic acid, and 5-[3-(4-nitrophenyl)-n-propyl]aminosalicylic acid. [Appendix 14] The method according to claim 13, wherein the compound of formula (I) is 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid. [Appendix 15] 13. The method of claim 12, wherein 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid is administered once daily at a dose of 1 mg / kg body weight to 200 mg / kg body weight. [Appendix 16] Administering a composition comprising: 1 mg to 1000 mg of a compound of formula (I), 60% w / w lactose monohydrate, 5% w / w croscarmellose sodium, 0.5% w / w magnesium stearate, and 1% w / w sodium lauryl sulfate 13. The method of claim 12, wherein the capsule comprises [Appendix 17] Administering a composition comprising: 1 mg to 1000 mg of a compound of formula (I), 42.7% w / w starch, 21.0% w / w crude protein; 14% w / w crude fat, 1.9% w / w crude fiber; Crude ash content of 6.1% w / w; 1.4% w / w arginine, 0.75% w / w calcium, 1.1% w / w lysine, 1.18% w / w methionine and cystine, and 0.5% w / w phosphorus The method according to claim 12, wherein the food composition comprises: [Appendix 18] Administering a composition comprising: 1 mg to 1000 mg of a compound of formula (I), 12.0% w / w crude protein; 1.5% w / w crude fat, 0.4% w / w crude fiber; Crude ash content of 1.5% w / w; 0.02% w / w calcium, 0.1% w / w potassium, and 78.0% w / w water 13. The method of claim 12, wherein the dietary supplement comprises [Appendix 19] Administering a composition comprising: 1 mg to 1000 mg of a compound of formula (I), 3% w / w of silicon dioxide, 0.05% w / w benzoic acid, 0.01% w / w sorbic acid, 5% w / w magnesium stearate, 20% w / w of cellulose, 40% w / w chicken source; 3% w / w dry yeast, and 19% w / w glucose 13. The method of claim 12, wherein the composition is a chewable tablet formulation comprising: [Appendix 20] 20. The method of any one of claims 12 to 19, wherein the cognitive and / or neurobehavioral disorder is selected from cognitive dysfunction syndrome, dysthymia, regressive depression and confusion syndrome.

Claims

1. 1. A pharmaceutical composition for use in treating a cognitive and / or neurobehavioral disorder in a companion animal in need thereof, wherein the cognitive and / or neurobehavioral disorder is selected from cognitive dysfunction syndrome (CDS), dysthymia, regressive depression and confusion syndrome, the pharmaceutical composition comprising 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, or a pharma- ceutical acceptable salt thereof.

2. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises 1 mg to 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid or a pharma- ceutically acceptable salt thereof.

3. 3. The pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutical composition is for oral administration.

4. (a) a pharmaceutical composition comprising: about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, about 50% w / w to about 70% w / w of lactose monohydrate; about 2% w / w to about 8% w / w of croscarmellose sodium; about 0.1% w / w to about 1% w / w of magnesium stearate, and About 0.1% w / w to about 2% w / w sodium lauryl sulfate Contains, or (b) the pharmaceutical composition comprises about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, Approximately 60% w / w lactose monohydrate, Croscarmellose sodium at about 5% w / w, About 0.5% w / w magnesium stearate, and Approximately 1% w / w sodium lauryl sulfate 4. The pharmaceutical composition according to claim 1, which is a capsule comprising:

5. (a) a pharmaceutical composition comprising: about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, about 30% w / w to about 50% w / w of starch; about 15% w / w to about 25% w / w crude protein; from about 10% w / w to about 20% crude fat; from about 0.1% w / w to about 5% w / w crude fiber; A crude ash content of about 1% w / w to about 10% w / w; about 0.1% w / w to about 5% w / w arginine; about 0.1% w / w to about 2.5% w / w of calcium; about 0.1% w / w to about 3% w / w of lysine; About 0.1% w / w to about 3% w / w of methionine and cystine, and About 0.1% w / w to about 2.5% w / w phosphorus Contains, or (b) the pharmaceutical composition comprises about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, about 42.7% w / w starch, Approximately 21.0% w / w crude protein; Approximately 14% w / w crude fat, Approximately 1.9% w / w crude fiber; Crude ash content of about 6.1% w / w; Arginine at about 1.4% w / w, Approximately 0.75% w / w calcium, about 1.1% w / w lysine, About 1.18% w / w methionine and cystine, and Approximately 0.5% w / w phosphorus 4. The pharmaceutical composition according to claim 1 , which is a food composition comprising:

6. (a) a pharmaceutical composition comprising: about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, from about 5% w / w to about 20% w / w crude protein; from about 0.1% w / w to about 5% w / w crude fat; from about 0.1% w / w to about 5% w / w crude fiber; A crude ash content of about 0.1% w / w to about 5% w / w; about 0% w / w to about 1% w / w of calcium; about 0% w / w to about 2% w / w of potassium, and Approximately 60% w / w to approximately 95% w / w water Contains, or (b) the pharmaceutical composition comprises about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, Approximately 12.0% w / w crude protein; Approximately 1.5% w / w crude fat, Approximately 0.4% w / w crude fiber; Crude ash content of about 1.5% w / w; Approximately 0.02% w / w calcium, About 0.1% w / w potassium, and Approximately 78.0% w / w water 4. The pharmaceutical composition according to claim 1, which is a dietary supplement comprising:

7. (a) a pharmaceutical composition comprising: about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, about 0.1% w / w to about 5% w / w of silicon dioxide; about 0% w / w to about 2% w / w of benzoic acid; about 0% w / w to about 1% w / w of sorbic acid; about 0.1% w / w to about 10% w / w of magnesium stearate; about 10% w / w to about 30% w / w of cellulose; about 30% w / w to about 50% w / w of a chicken meat source; about 0.1% w / w to about 5% w / w of dry yeast, and About 10% w / w to about 30% w / w glucose Contains, or (b) the pharmaceutical composition comprises about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, about 3% w / w silicon dioxide, Benzoic acid at about 0.05% w / w, about 0.01% w / w sorbic acid, about 5% w / w magnesium stearate, Approximately 20% w / w cellulose, Approximately 40% w / w chicken source, About 3% w / w dry yeast, and Approximately 19% w / w glucose 4. The pharmaceutical composition according to any one of claims 1 to 3, which is a chewable tablet formulation comprising:

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the cognitive and / or neurobehavioral disorder is a cognitive dysfunction syndrome.

9. The pharmaceutical composition comprises (a) Simultaneous pharmacological inhibition of oxidative stress and inflammation; (b) inhibiting oxidative stress and prostaglandin E2 synthesis; or (c) Inhibiting oxidative stress and microsomal prostaglandin E synthase 1 The pharmaceutical composition according to any one of claims 1 to 8, for treating CDS by

10. A pharmaceutical composition described in any one of claims 1 to 9, wherein 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid is administered in a dose of 1 mg / kg body weight to 200 mg / kg body weight once a day.

11. A pharmaceutical composition described in any one of claims 1 to 9, wherein 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid is administered at a dose of about 0.1 mg / kg body weight to about 30 mg / kg body weight once a day.

12. A pharmaceutical composition described in any one of claims 1 to 9, wherein 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid is administered at a dose of about 0.1 mg / kg body weight to about 10 mg / kg body weight once a day.

13. 13. The pharmaceutical composition of any one of claims 1 to 12, wherein the companion animal is selected from cats, chinchillas, dogs, ferrets, gerbils, guinea pigs, hamsters, hedgehogs, mice, rabbits and rats.

14. 14. The pharmaceutical composition of any one of claims 1 to 13, wherein the companion animal is a dog.

15. 14. The pharmaceutical composition of any one of claims 1 to 13, wherein the companion animal is a cat.

16. A pharmaceutical composition described in any one of claims 1 to 14, wherein the pharmaceutical composition improves cognitive function in dogs for at least 8 weeks.

17. (a) the pharmaceutical composition improves cognitive function in a dog from severe to moderate, mild, or normal levels; or (b) the pharmaceutical composition restores near-normal cognitive function to the dog; 17. A pharmaceutical composition according to any one of claims 1 to 14 and 16.

18. 18. The pharmaceutical composition of claim 16 or 17, wherein the cognitive function is selected from improvement in social interaction, proper toileting, spatial orientation, and sleep-wake activity cycles.

19. 1. Use of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a cognitive and / or neurobehavioral disorder, comprising: The treatment comprises administering 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid or a pharma- ceutically acceptable salt thereof to a companion animal in need thereof; The cognitive and / or neurobehavioral disorder is selected from cognitive dysfunction syndrome (CDS), dysthymia, retrograde depression and confusion syndrome.

20. 20. The use according to claim 19, wherein the medicament comprises between 1 mg and 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid or a pharma- ceutically acceptable salt thereof.

21. 21. The use according to claim 19 or 20, wherein the medicament is for oral administration.

22. (a) The medicine is about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, about 50% w / w to about 70% w / w of lactose monohydrate; about 2% w / w to about 8% w / w of croscarmellose sodium; about 0.1% w / w to about 1% w / w of magnesium stearate, and About 0.1% w / w to about 2% w / w sodium lauryl sulfate Contains, or (b) The medicine is 1 mg to 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 60% w / w lactose monohydrate, 5% w / w croscarmellose sodium, 0.5% w / w magnesium stearate, and 1% w / w sodium lauryl sulfate 22. The use according to any one of claims 19 to 21, which is a capsule comprising:

23. (a) The medicine is about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, about 30% w / w to about 50% w / w of starch; about 15% w / w to about 25% w / w crude protein; from about 10% w / w to about 20% crude fat; from about 0.1% w / w to about 5% w / w crude fiber; A crude ash content of about 1% w / w to about 10% w / w; about 0.1% w / w to about 5% w / w arginine; about 0.1% w / w to about 2.5% w / w of calcium; about 0.1% w / w to about 3% w / w of lysine; About 0.1% w / w to about 3% w / w of methionine and cystine, and About 0.1% w / w to about 2.5% w / w phosphorus Contains, or (b) The medicine is 1 mg to 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 42.7% w / w starch, 21.0% w / w crude protein; 14% w / w crude fat, 1.9% w / w crude fiber; Crude ash content of 6.1% w / w; 1.4% w / w arginine, 0.75% w / w calcium, 1.1% w / w lysine, 1.18% w / w methionine and cystine, and 0.5% w / w phosphorus 22. The use according to any one of claims 19 to 21, which is a food composition comprising:

24. (a) The medicine is about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, from about 5% w / w to about 20% w / w crude protein; from about 0.1% w / w to about 5% w / w crude fat; from about 0.1% w / w to about 5% w / w crude fiber; A crude ash content of about 0.1% w / w to about 5% w / w; about 0% w / w to about 1% w / w of calcium; about 0% w / w to about 2% w / w of potassium, and Approximately 60% w / w to approximately 95% w / w water Contains, or (b) The medicine is 1 mg to 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 12.0% w / w crude protein; 1.5% w / w crude fat, 0.4% w / w crude fiber; Crude ash content of 1.5% w / w; 0.02% w / w calcium, 0.1% w / w potassium, and 78.0% w / w water 22. The use according to any one of claims 19 to 21, which is a dietary supplement comprising:

25. (a) The medicine is about 1 mg to about 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, about 0.1% w / w to about 5% w / w of silicon dioxide; about 0% w / w to about 2% w / w of benzoic acid; about 0% w / w to about 1% w / w of sorbic acid; about 0.1% w / w to about 10% w / w of magnesium stearate; about 10% w / w to about 30% w / w of cellulose; about 30% w / w to about 50% w / w of a chicken meat source; about 0.1% w / w to about 5% w / w of dry yeast, and About 10% w / w to about 30% w / w glucose Contains, or (b) The medicine is 1 mg to 1000 mg of 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid, 3% w / w of silicon dioxide, 0.05% w / w benzoic acid, 0.01% w / w sorbic acid, 5% w / w magnesium stearate, 20% w / w of cellulose, 40% w / w chicken source; 3% w / w dry yeast, and 19% w / w glucose 22. The use according to any one of claims 19 to 21, which is a chewable tablet formulation comprising:

26. 26. The use according to any one of claims 19 to 25, wherein the cognitive and / or neurobehavioral disorder is a cognitive dysfunction syndrome.

27. Medicines are (a) Simultaneous pharmacological inhibition of oxidative stress and inflammation; (b) inhibiting oxidative stress and prostaglandin E2 synthesis; or (c) Inhibiting oxidative stress and microsomal prostaglandin E synthase 1 27. The use according to any one of claims 19 to 26, for treating CDS by

28. The use described in any one of claims 19 to 27, wherein 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid is administered in a dose of 1 mg / kg body weight to 200 mg / kg body weight once a day.

29. The use described in any one of claims 19 to 27, wherein 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid is administered at a dose of about 0.1 mg / kg body weight to about 30 mg / kg body weight once a day.

30. The use described in any one of claims 19 to 27, wherein 2-hydroxy-5-[2-(4-trifluoromethyl-phenyl)-ethylamino]-benzoic acid is administered at a dose of about 0.1 mg / kg body weight to about 10 mg / kg body weight once a day.

31. 31. The use according to any one of claims 19 to 30, wherein the companion animal is selected from cats, chinchillas, dogs, ferrets, gerbils, guinea pigs, hamsters, hedgehogs, mice, rabbits and rats.

32. 32. The use according to any one of claims 19 to 31, wherein the companion animal is a cat.

33. 32. The use according to any one of claims 19 to 31, wherein the companion animal is a dog.

34. 34. The use according to any one of claims 19 to 31 and 33, wherein the medicament improves cognitive function in dogs for at least 8 weeks.

35. (a) the medication improves the dog's cognitive function from severe to moderate, mild, or normal; or (b) the medication restores near-normal cognitive function to the dog.

35. Use according to any one of claims 19 to 31, 33 and 34.

36. 36. The use according to claim 34 or 35, wherein the cognitive function is selected from improvement in social interaction, proper toileting, spatial orientation, and sleep-wake activity cycles.

Citation Information

Patent Citations

  • - Amino salicylic acid derivative, a salt thereof, their preparation and pharmaceutical compositions containing them

    JP1987501703A

  • Tetrafluorobenzyl derivative and pharmaceutical composition for prevention and treatment of acute and degenerative neurological diseases containing the same

    JP2005529972A

  • Pharmaceutical uses of 5-benzylaminosalicylic acid derivatives or salts thereof

    JP2012517424A

  • Compounds, Compositions and Methods for PreventingNeurodegeneration in Acute and Chronic Injuries in theCentral Nervous System

    KR1020030058934A

  • Compounds and compositions for treating neuronal death or neurological dysfunction

    US20070298129A1